Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)
Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This phase I, open label dose escalation study will investigate the addition of BIBF 1120 to
treatment with the combination of carboplatin and Pegylated Liposomal Doxorubicin (PLD) in
patients with advanced, platinum sensitive relapsed ovarian cancer, fallopian tube carcinoma
or primary peritoneal cancer. Patients will be treated with BIBF 1120 together with
carboplatin and PLD in up to 6-9 repeated 28 days treatment courses until disease progression
is observed.